Trial Profile
Efficacy and safety of house dust mite allergy immunotherapy (Alutard SQ) in paediatric and adult patients with mild-to-moderate asthma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy injection ALK Abello (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.